NCT02107950View on ClinicalTrials.gov

Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

November 30, 2016

Study Completion Date

May 17, 2017

Conditions

Ovarian NeoplasmsOvarian Cancer (OvCa)Ovarian Epithelial Cancer

Interventions

BIOLOGICAL

DCVAC/OvCa in parallel with chemotherapy

DCVAC/OvCa is the experimental therapy added on to Carboplatin and Gemcitabine

DRUG

Standard of Care

Carboplatin and Gemcitabine is Standard of Care First Line Chemotherapy

Trial Locations (16)

50931

Cologne

625 00

Brno

656 53

Brno

370 01

České Budějovice

500 05

Hradec Králové

741 01

Nový Jičín

755 20

Olomouc

708 52

Ostrava

128 08

Prague

150 06

Prague

01307

Dresden

91 054

Erlangen

15-276

Bialystok

31-501

Krakow

20-081

Lublin

60-569

Poznan

All Listed Sponsors

lead

SOTIO a.s.

INDUSTRY

NCT02107950 - Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma | Biotech Hunter | Biotech Hunter